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Abstract
The prediction of allergen cross-reactivity is currently largely based on linear sequence
data, but will soon include 3D information on homology among surface exposed
residues. To evaluate procedures for these predictions, we need ways to quantitatively
assess actual cross-reactivity between two allergens. Three parameters are mentioned:
1) the fraction of the epitopes that is cross-reactive; 2) the fraction of IgE that is cross-
reactive; 3) the relative affinity of the interaction between IgE and the two allergens.
This editorial briefly compares direct binding protocols with the often more
appropriate reciprocal inhibition protocols. The latter type of protocol provides
information on symmetric versus asymmetric cross-reactivity, and thus on the
distinction between complete (= sensitising) allergens versus incomplete, cross-reacting
allergens. The need to define the affinity threshold of the assay and a caveat on the use
of serum pools are also discussed.
In a paper recently published in this Journal, the question
was raised whether a fungus considered for biological pest
control (Beauvaria bassiana) could elicit allergic reactions
due to cross-reactive IgE antibodies induced by allergens
from known allergenic fungi [1]. Based on homology in
the amino acid sequence, four potentially cross-reactive
proteins were cloned, expressed in E coli and tested for IgE
(cross)reactivity using sera from patients with known fun-
gal allergies. Support for (cross)reactivity was found for
two of these four proteins. The two (cross)reactive pro-
teins had the highest sequence homology to known aller-
gens: the enolase was 85% sequence-identical to the
Alternaria enolase known as Alt a 6 and the aldehyde
dehydrogenase was 71% sequence-identical to the Alter-
naria dehydrogenase Alt a 10. The two proteins with no
demonstrable (cross)reactivity had sequence identities of
51 and 60% to two Aspergillus fumigatus proteins. It is
tempting to conclude that this result supports the notion
that sequence identity is a useful predictor of cross-reactiv-
ity.
A few comments on the prediction on cross-reactivity as
illustrated by this study. As the authors point out, the
number of sera used to test for cross-reactivity was small
(N = 20, tested as 10 pools of 2; a caveat on the use of
serum pools will be discussed later). Moreover, the clini-
cal history of the patients is not specified, which is partic-
ularly relevant in view of the quite distinct modes of
allergen exposure in case of invasive aspergillosis as com-
pared to airborne Alternaria. IgE reactivity was investi-
gated by immunoblotting of crude E. coli extracts as the
source of the recombinant proteins, which is useful but
not ideal since it is known to be inefficient for some aller-
gens. Lastly, as discussed in more detail below, cross-reac-
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tive potential, particularly in case of polyclonal
antibodies, is more reliably assessed by inhibition tests
than by direct binding tests.
Cross-reactivity and allergenicity
For various reasons, often related to regulatory safety
issues, a discussion is ongoing on prediction of allergenic-
ity. This involves both prediction of de novo allergenicity
as well as prediction of cross-reactivity. The latter, predic-
tion of allergen cross-reactivity, is the topic of this com-
munication, with emphasis on quantitative and
methodological aspects.
Clinically, allergic cross-reactivity is often encountered as
symptoms without prior exposure. Another common clin-
ical situation is the occurrence of symptoms upon expo-
sure to allergenic sources that are unlikely to sensitise,
such as apples. In Northern Europe it is rare to find apple
allergy in the absence of birch allergy. The major birch
pollen allergen acts as the sensitizer or primary allergen,
which by definition is able to trigger the immune system
to produce IgE antibodies. The homologous protein in
apple Mal d 1 is an incomplete allergen, because it is una-
ble (or: extremely inefficient) to induce IgE antibodies,
but is able to elicit symptoms due to its ability to trigger
mast cells loaded with IgE anti-Bet v 1.
Cross-reactivity is sometimes seen as a property of a sub-
group of antibodies: antibodies to some epitopes (recur-
ring epitopes such as cross-reactive carbohydrate
determinants (CCDs [2]) are more likely to be cross-reac-
tive than antibodies to other epitopes. However, it is often
more appropriate to use cross-reactivity to describe a rela-
tion between two allergens (which I will refer to as Ag1
and Ag2; alternatively, I will use the birch allergen Bet v 1
and the cross-reactive apple allergen Mal d 1 as examples):
the closer the similarity between two allergens, the more
likely it is to find a cross-reactive antibody. In either case,
the concept of cross-reactivity concerns (at least) three
rather than two reagents: two allergens and an antibody.
Since it is impossible to test all antibodies, we have to live
with the frustrating thought that it is impossible to prove
that two allergens completely lack cross-reactivity. Con-
versely, it is also impossible to prove that they are fully
cross-reactive. It is all a matter of probability, which in
many cases is either very close to 0 or very close to 1. In
many other cases it is, however, easy to demonstrate some
cross-reactivity.
Prediction of cross-reactivity from the amino 
acid sequence
Antibodies largely bind to surface patches of folded pro-
teins (epitopes), so knowledge of the full 3D structures of
the target protein and the related allergens would clearly
be an advantage for such a prediction and now more com-
monly available (or the 3D structures can be reliably pre-
dicted). Undoubtedly, cross-reactivity prediction
algorithms will be developed in which such information
is incorporated. However, sufficiently reliable informa-
tion on the relevant 3D structures is often not available
and the prediction has to be based on the linear amino
acid sequence. One of the points of debate is whether
short stretches of 6–8 fully identical amino acids are reli-
able predictors and should be used in combination with
partial amino acid identity of longer stretches (typically
more than 35% identity between stretches of 80 amino
acids [3]).
Other issues related to prediction of cross-reactivity, such
as the repertoire-modifying effect of a human homologue,
the contribution of post-translational modification (par-
ticularly non-mammalian glycosylation patterns), the
possibilities and limitations of peptides as epitope mimics
and the intriguing question whether IgE antibodies tend
to be more cross-reactive than IgG antibodies, with its
possible link with positive and negative regulation of B
cells by IgE versus IgG antibodies, have been discussed
elsewhere [4-6].
Symmetric versus asymmetric cross-reactivity
Some situations of allergen cross-reactivity are almost triv-
ial, such as the cross-reactivity between major allergens of
botanically-related grasses [7] and between major dust
mite allergens. Without information on allergen exposure
it is then virtually impossible to decide which allergen is
the sensitizer. Symmetric cross-reactivity a likely possibil-
ity: both allergens in the couple can sensitize and both can
largely (but not completely) inhibit the binding of IgE to
the other allergen (figure 1A). In the birch/apple situation
the situation is different (at least in Northern Europe) [8].
Cross-reactivity is asymmetric (figure 1B), as can be dem-
onstrated in vitro by reciprocal IgE antibody neutraliza-
tion. The usual finding is that birch allergen inhibits IgE
binding to the apple allergen similar to or even better than
the inhibition found by using equimolar amounts of the
apple allergen as inhibitor, whereas the apple allergen
only partially inhibits IgE binding to the birch allergen.
Issues on the quantification of the degree of 
cross-reactivity of two allergens
First, a semantic issue: polyclonal versus monoclonal
cross-reactivity. The word "cross-reactivity" is used differ-
ently in the polyclonal situation and the monoclonal sit-
uation. Traditionally, it is used to describe the polyclonal
situation as encountered in the body. Many different anti-
bodies recognize Ag1 (for example: Bet v 1). Some of these
antibodies react with Ag2 (Mal d 1). The degree of cross-
reactivity can be expressed as the fraction of anti-Bet v 1
antibodies that react with Mal d 1. This fraction will vary
between individuals and usually varies within one indi-Clinical and Molecular Allergy 2007, 5:2 http://www.clinicalmolecularallergy.com/content/5/1/2
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vidual in time. A cross-reactive polyclonal antiserum can
often be made mono-specific by absorption with either
Ag1 or Ag2. When this type of cross-reactivity assessment
is applied to a single monoclonal antibody, the unavoida-
ble outcome would seem to be either: "fully cross-reac-
tive" or: "not cross-reactive". This is intuitively
unsatisfactory, since "fully cross-reactive" suggests equal
reactivity of the antibody with Ag1 and Ag2, whereas in
most cases the antibody will have different affinities for,
and thus preferentially react with, either Ag1 or Ag2. An
important qualitative modifier (which is mostly not spec-
ified in papers on cross-reactivity) is the affinity threshold,
which depends on the read-out system and the concentra-
tions used for testing. The effects of affinity are most visi-
ble in the monoclonal situation, but also play a role in the
polyclonal situation. In general, a cross-reactive antigen
will have a lower affinity than the antigen that induced the
antibody response. It is not clear below which affinity the
cross-reactivity becomes irrelevant, but it is important to
appreciate that there is a grey area. In clinical terms, a low
affinity may translate into a high threshold for the cross-
reactive allergen and/or milder symptoms.
In biological systems (e.g. skin test, cellular in vitro
assays), assessment of cross-reactivity largely depends on
direct testing, and thus on statistical associations. This is
particularly unconvincing if not only the antibodies are
polyclonal, but also the allergens are tested as allergen
extracts (i.e. allergen mixtures). More reliable analysis is
possible in vitro. In the case of monoclonal antibodies,
direct binding assays can be used (figure 2). Also with pol-
yclonal antibodies (typically from human serum) direct
Symmetric (figure 1A) versus asymmetric (figure 1B) cross-reactivity Figure 1
Symmetric (figure 1A) versus asymmetric (figure 1B) cross-reactivity. Symmetric cross-reactivity (figure 1A) occurs between 
major allergens from related grasses or dust mites. Asymmetric cross-reactivity (figure 1B) is usually found for example 
between the birch allergen Bet v 1 (outer circle) and the related protein from apple, Mal d 1 (inner circle). Bet v 1 completely 
inhibits IgE binding to Mal d 1, but Mal d 1 only partially inhibits IgE binding to Bet v 1 (see also figures 2 and 3).Clinical and Molecular Allergy 2007, 5:2 http://www.clinicalmolecularallergy.com/content/5/1/2
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binding assays can be used and could, theoretically, pro-
vide information on one of the parameters in cross-reac-
tivity assessment: the fraction of the epitopes that is cross-
reactive. This is reflected in the relative IgE binding
obtained at saturating IgE antibody doses (which corre-
sponds to the vertical distance between the high-dose seg-
ments of two dose-response curves as indicated in figure
2). In practice, this is not a trivial analysis. Moreover, such
a direct-binding test does not discriminate between cross-
reacting and non-crossreacting IgE. Cross-reactivity can be
proven (and to a certain extent quantified) by reciprocal
inhibition systems, preferably with at least one purified
single allergen (figure 3). The two other parameters in
cross-reactivity assessment can be derived from such
measurements: 1) the fraction of IgE that is cross-reactive
(the vertical distance between the homologous and heter-
ologous dose response curves when testing the complete
allergen on the solid phase at saturating inhibitor levels as
indicated in figure 3A) and 2) the relative affinity of the
interaction between IgE and the two allergens (the hori-
zontal distance between the homologous and heterolo-
gous dose response curves when testing the incomplete
allergen on the solid phase, as indicated in figure 3B).
If a serum with cross-reactive antibody to the birch allergen Bet v 1 is incubated with Bet v 1 on the solid-phase, the binding  curve is different in two ways: 1) it rises to a higher level and 2) it is shifted to the left compared to the binding observed with  the cross-reactive apple allergen Mal d 1 on the solid phase Figure 2
If a serum with cross-reactive antibody to the birch allergen Bet v 1 is incubated with Bet v 1 on the solid-phase, the binding curve is dif-
ferent in two ways: 1) it rises to a higher level and 2) it is shifted to the left compared to the binding observed with the cross-reactive 
apple allergen Mal d 1 on the solid phase. The first observation reflects that only a fraction of the epitopes is cross-reactive (in this exam-
ple: 50%, as indicated by the vertical arrow). The second observation reflects that only a fraction of the antibodies is cross-reactive, but 
also that the affinity is usually lower for the cross-reactive allergen (Mal d 1) compared to the sensitising allergen (Bet v 1). In these model 
calculations, the concentration of Bet v 1 epitopes is set at 1; 50% of these epitopes are assumed have a cross-reactive homologue in Mal 
d 1; 40% of the IgE antibodies are assumed to be cross-reactive. The upper curve represents binding to Bet v 1, assuming a dissociation 
constant KD equal to 1. The next 3 curves represent binding to Mal d 1 at decreasing affinities (KD equal to 1, 5 and 25, respectively. Note 
that this type of experiment does not prove cross-reactivity. The observed binding could in theory also be due to co-sensitization. This 
can be investigated by inhibition assays (see figure 3).Clinical and Molecular Allergy 2007, 5:2 http://www.clinicalmolecularallergy.com/content/5/1/2
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Model calculations illustrating the use of cross-inhibition to demonstrate cross-reactivity and to distinguish the primary sensi- tising birch allergen Bet v 1 from the cross-reactive (incomplete, non-sensitizing) apple allergen Mal d 1 Figure 3
Model calculations illustrating the use of cross-inhibition to demonstrate cross-reactivity and to distinguish the primary sensi-
tising birch allergen Bet v 1 from the cross-reactive (incomplete, non-sensitizing) apple allergen Mal d 1. The type of experi-
ment shown in figure 3A indicates what percentage of the IgE antibodies is cross-reactive (in this example: 40%, as indicated by 
the vertical arrow). The type of experiment shown in figure 3B shows that Bet v 1 inhibits all antibodies to Mal d 1 and pro-
vides a crude estimate of the relative affinity of the interaction of the IgE antibodies with the two allergens (if the concentration 
of the antibody as well as the solid-phase allergen is equal to or below the KD of the IgE-allergen interaction), as indicated by 
the two horizontal arrows. The parameter setting correspond to those used in figure 2, using an IgE concentration of 1, which 
corresponds to values for uninhibited binding of IgE of 0.2660 for IgE binding to Bet v 1 in figure 3A (KD = 1), and for IgE bind-
ing to Mal d 1 of 0.0077, 0.0341 and 0.1118 (KD = 25, 5 or 1, respectively) in figure 3B.Publish with BioMed Central    and   every 
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A caveat on the use of serum pools
As discussed above, cross-reactivity is largely a probability
feature. For this reason, it is rarely meaningful to test only
one single serum. It is preferable to test a large number of
individual sera and pool the results by conventional sta-
tistical procedures. However, the use of a serum pool
rather than a large number of individual sera is, obvi-
ously, economical: fewer tests need to be performed and
smaller volumes of (often precious) allergic serum sam-
ples are needed. From the statistical point of view it is
important to inversely adjust the volumes of serum to be
pooled according to their antibody titre: the higher the
titre, the smaller to contributing volume should be. Opti-
mally, the amount of antibody contributed by each serum
donor should be similar (typically within a factor 2).
Without such a precaution, it is likely that the pool will
behave like a dilution of the strongest serum.
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